Synthesis, crystal structure and anticancer activity of novel derivatives of ethyl 1-(4-oxo-8-aryl-4,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3-yl)formate
作者:Krzysztof Sztanke、Jolanta Rzymowska、Maciej Niemczyk、Izabela Dybała、Anna E. Kozioł
DOI:10.1016/j.ejmech.2006.01.016
日期:2006.4
Synthesis and anticancer activity of ethyl 1-(4-oxo-8-aryl-4,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3-yl)formates (7-12) are presented. The title compounds were obtained by two independent synthesis methods from 1-aryl-2-hydrazono-imidazolidines (1-aryl-2-hydrazino-imidazolines) (1-6) by cyclocondensation reaction with diethyl 2-(hydroxyimino)malonate (A) and diethyl 2-oxomalonate (B). Molecular
1-(4-氧代-8-芳基-4,6,7,8-四氢咪唑并[2,1-c] [1,2,4]三嗪-3-基)格式(7- 12)介绍。通过两种独立的合成方法,通过与2-(羟基亚氨基)丙二酸二乙酯(A)进行环缩合反应,从1-芳基-2-肼基-咪唑啉(1-芳基-2-肼基-咪唑啉)(1-6)获得标题化合物。和2-氧代己二酸二乙酯(B)。合成的化合物的分子结构通过IR,(1)H NMR,EI-MS光谱,元素分析和X射线晶体学确认。12.化合物10和11对以下癌细胞具有抗癌活性:LS180(ECACC 87021202,人类高加索人)结肠腺癌细胞),SiHa(ECACC 85060701,子宫癌细胞),T47D(ECACC 85102201,人乳腺癌细胞)。已发现化合物10对SiHa癌症系最有活性;在两种检测浓度下(10和50微克ml(-1)),其GI分别为41%和52%,而化合物11具有最大的潜力来减少LS180